Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

8Total
P 1 (4)
P 2 (3)
P 3 (1)

Trial Status

Recruiting8

Clinical Trials (8)

Showing 8 of 8 trials
NCT07713732Phase 1Recruiting

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

NCT07174427Phase 3RecruitingPrimary

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

NCT07613723Phase 1Recruiting

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

NCT05227326Phase 1Recruiting

AOH1996 for the Treatment of Refractory Solid Tumors

NCT06571734Phase 2Recruiting

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

NCT06607692Phase 1Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT07173972Phase 2Recruiting

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

NCT07169344Phase 2Recruiting

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Showing all 8 trials

Research Network

Activity Timeline